The Application of Multiplate Resazurin Reduction Assay in The Screening for Anti-Mycobacterial Activity from Indonesian Medicinal Plants

Martha Sari, Gita Syahputra, Wien Kusharyoto

Abstract


Tuberculosis (TB) is an airborne illness generated by Mycobacterium tuberculosis (Mtb), also one of the prominent infectious killers of adults worldwide. There is a pressing need to expand novel anti-mycobacterial drugs because of the increasing resistance of pathogenic mycobacteria to existing antibiotics. Native compounds acquired from microbial resources and medicinal cultivars have played an essential part as the origin of TB medications. The microplate resazurin reduction assay (MRRA) is generally utilized to assess natural and synthetic compounds for anti-mycobacterial activity. In our work, the MRRA method was employed to evaluate the anti-mycobacterial activity of extracts from curative plants using Mycobacterium smegmatis and Mycobacterium bovis BCG and to compare them to rifampicin as an anti-mycobacterial drug. The optimized MRRA utilized 2% aqueous DMSO and 62.5 μg/mL resazurin as an indicator compound in 5% aqueous Tween 80. The optimal incubation time for M. smegmatis was 24 hours, and for M. bovis BCG was 48 hours. The methanolic plant extracts were acquired from various Indonesian medicinal plants known to have anti-mycobacterial activity. The MRRA method using M. smegmatis or M. bovis BCG as anti-mycobacterial targets offers a distinct advantage such as low-cost, rapid, and safe screening for anti-mycobacterial activity in a middle to high-through-put-format.


Keywords


Anti-mycobacterial, phytochemical extracts, Indonesian medicinal plants, MRRA

Full Text:

PDF

References


Abdul ABH., Al ZAS., Tailan ND., Wahab SIA., Zain ZNM., Ruslay S., and Syam MM., 2008. Anti-cancer activity of natural compound (Zerumbone) extracted from Zingiber zerumbet in human Hela cervical cancer cells. Int J Pharmacol. 4(3): 160-168. DOI: 10.3923/ijp.2008.160.168.

Abidi., Syed H., Ahmed K., Sherwani., Sikander K., Bibi., Nazia-Kazmi., Shahana U., 2014. Detection of Mycobacterium smegmatis biofilm and its control by natural agents. Int J Curr Microbiol Appl Sci. 3(4): 801-812.

Altaf M., Miller CH., Bellow DS., and O'Toole R., 2010. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb), 90(6): 333-7. DOI: 10.1016/j.tube.2010.09.002.

Banfi E., Scialino G., and Monti-Bradgadin C., 2013. Development of microdilution method to evaluate Mycobacterium tuberculosis drug susceptibility. J Antimicrob Chemother. 52: 796-800. DOI: 10.1093/jac/dkg439.

Bhowmik., Debjit., Gopinath., Harish., Kumar B., Pragati., Duraivel SG., Aravind-Kumar KP., and Sampath., 2013. Medicinal uses of Punica granatum and its health benefits. J Pharmacogn Phytochem. 1 (5): 81-92.

Carpenter CD., O’Neill T., Picot N., Johnson JA., Robichaud GA., Webster D-Gray., Christopher A., 2012. Anti-mycobacterial natural products from the Canadian medicinal plant Jupenirus communis. J Ethnopharmacol. 143: 695-700. DOI: 10.1016/j.jep.2012.07.035.

Coelho RG., Honda NK., Vieira MC., Brum RL., Pavan FR., Leite CQ., Fujimura-Cardoso., Claudia AL., 2010. Chemical composition and antioxidant and antimycobacterial activities of Bromelia balance (Bromeliaceae). J Med Food. 13(5): 1277-1280. DOI: 10.1089/jmf.2009.0032.

Dheda K., Gumbo T., Gandhi NR., Murray M., Theron G., Udwadia Z., Migliori GB., Warren R., 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2(4): 321-38. DOI: 10.1016/S2213-2600(14)70031-1.

Ekor M., 2013. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 4: 177. DOI: 10.3389/fphar.2013.00177.

Field SK., 2015. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. The Adv Chronic Dis. 6(4): 170–184. DOI: 10.1177/2040622315582325.

García V., Palma JP., Nicolás & Rivera G., 2012. Recent advances in antitubercular natural products. Eur J Med Chem. 49: 1-23. DOI: 10.1016/j.ejmech.2011.12.029.

Gupta V., Gupta A., Arora S., Bambery P., Dogra MR and Agarwal A., 2003. Presumed tubercular serpiginous-like choroiditis: clinical presentations and management. Ophthalmology. 110(9): 1744-9. DOI: 10.1016/S0161-6420(03)00619-5.

Ishola IO., Akinyede AA., Robert AK., Omilabu SA., 2015. Hepatoprotective and antioxidant activities of Hepacare, a herbal formulation against carbon tetrachloride-induced liver injury. Drug research. 65: 30-39. DOI: 10.1055/s-0034-1371829.

Kadir FA., Kassim NM., Abdulla MA., Kamalidehghan B., Ahmadipour F., and Yehye, WA., 2014. PASS-predicted hepatoprotective activity of Caesalpinia sappan in thioacetamide-induced liver fibrosis in rats. Journal of Scientific World. 2014:301879. DOI: 10.1155/2014/301879.

Lewis, JM and Sloan DJ., 2015. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag, 11: 779–791. DOI: 10.2147/TCRM.S71076.

Lewis JM., Hine P., Walker J., Khoo SH., Taegtmeyer M., Squire SB and Sloan DJ., 2016. First experience of effectiveness and safety of bedaquiline for 18 months within an optimized regimen for XDR-TB. Eur Respir J. 47(5): 1581-1584. DOI: 10.1183/13993003.01980-2015.

Liang CH., 2013. Brazilein from Caesalpinia sappan L. antioxidant inhibits adipocyte differentiation and induces apoptosis through caspase-3 activity and anthelmintic activities against Hymenolepis nana and Anisakis simplex. Evid Based Complement Alternat Med. 864892: 1-14. DOI: 10.1155/2013/864892.

Lienhardt C., Raviglione M., Spigelman M., Hafner R., Jaramillo E., Hoelscher M., Zumla A and Gheuens J., 2012. New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospect for the future. J Infect Dis. 205: 241-249. DOI: 10.1093/infdis/jis034.

Lucci P., Pacetti D., Loizzo MR., and Frega NG., 2015. Punica granatum cv. Dente di Cavallo seed ethanolic extract: antioxidant and antiproliferative activities. Food Chem. 16: 475-483. DOI: 10.1016/j.foodchem.2014.06.123.

Maiga M., Lun S., Guo H., Winglee K., Ammerman NC., and Bishai WR., 2012. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J Infect Dis. 205(11): pp. 1705–1708. DOI: 10.1093/infdis/jis269.

Martin S., Camachi M., Portaels F., and Palomino J., 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother. 47(11): 3616-3619. DOI: 10.1128/AAC.47.11.3616-3619.2003.

Migliori GB., Centis R., D’Ambrosio L., Spanevello A., Borroni E., Cirillo DM and Sotgiu G., 2013. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?. Clint Infect Dis. 54: 1379-1380. DOI: 10.1093/cid/cis128.

Murugasu OB., and Dick T., 2000. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother. 46: 917-919. PMID: 11102410.

Newman DJ and Cragg GM., 2016. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 79(3): 629-61. DOI: 10.1021/acs.jnatprod.5b01055.

O’Neill TE., Johnson JA., Webster D., Gray CA., 2010. The Canadian medicinal plant Heracleum maximum contains antimycobacterial diynes and furanocoumarins. J Ethnopharmacol.147: 232-237. DOI: 10.1016/j.jep.2013.03.009.

O’Neill TE., Li H., Colquhoun CD., Johnson JA., Webster D., and Gray CA., 2014. Optimization of the microplate resazurin assay for screening and bioassay-guided fractionation of phytochemical extracts against Mycobacterium tuberculosis. Phytochem Anal. 10: 1002. DOI: 10.1002/pca.2516.

Phongpaichit S., Vuddhakul V., Subhadhirasakul S., Wattanapiromsakul C., 2006. Evaluation of the antimycobacterial activity of extracts from plants used as self-medication by AIDS patients in Thailand. Pharm Biol. 44(1): 71–75. https://doi.org/10.1080/13880200500531060.

Primm TP., and Franzblau SG., 2007. Recent advances in methodologies for the discovery of antimycobacterial drugs. Curr Bioact Compd. 3: 201–208. DOI: 10.2174/157340707781695550.

Razmavar S., Abdulla MA., Ismail SB., and Hassandarvish P., 2014. Antibacterial activity of leaf extracts of Baeckea frustescens against Methicillin-resistant Staphylococcus aureus. BioMed Res Int. 2014: 521287. http://dx.doi.org/10.1155/2014/521287.

Rianto S., 2007. Identification of the isolated compounds from Zingiber amaricans BL. Rhizome. Indo J Chem. 7(1): 93-96. https://doi.org/10.22146/ijc.21720.

Salomon CE., and Schmidt LE., 2012. Natural products as leads for tuberculosis drug development. Curr Top Med Chem. 12(7): 735-65. PMID: 22283816.

Schafer MP., Fernback JE., and Ernst MK., 1999. Detection and characterization of airborne Mycobacterium tuberculosis H37Ra particles, a surrogate for airborne pathogenic M. tuberculosis. Aerosol Sci Technol. 30: 161–173. https://doi.org/10.1080/027868299304750.

Singh CB., Chanu SB., K Lenin., Swapana N., Cantrell C., and Ross S A., 2014. Chemical composition and biological activity of the essential oil of rhizome of Zingiber zerumbet (L) Smith. J Pharmacogn Phytochem. 3(3): 130-133. https://pubag.nal.usda.gov/catalog/62328.

Sivakumar A., and Jayaraman G., 2011. Anti-tuberculosis activity of commonly used medicinal plants of South India. J Med Plants Res. 5(31): 6881-6884. https://doi.org/10.5897/JMPR11.1397.

Srinivasan R., Selvam G., Ganapathy K., Sakthivel M., Krishnamurthy BR., Karthikeyan M., Gopi M., and Govindasamy C., 2012. In vitro antimicrobial activity of Caesalpinia sappan L. Asian Pac J Trop Biomed. 2(1): S136-S139. https://doi.org/10.1016/S2221-1691(12)60144-0.

Szumowski L., 2015. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Dev Ther. 9: 677–682. DOI: 10.2147/DDDT.S60923.

Tadolini M., Garcia-Prats., Anthony JD., Lia H., Catherine C., Rosella SH., Simon MBJ., Ferreira H., Caminero JA., Jonckheere S., Sinha A., Herboczek K., Khaidarkhanova Z., Hayrapetyan A., Khachatryan N., Urtkmelidze LC., Esposito S., Matteelli A., Furin JV., Francis-Migliori, Giovanni B., 2016. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J. 48(3): 938-943. DOI: 10.1183/13993003.00705-2016.

Taneja NK., and Tyagi JS., 2007. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother. 10: 1093. DOI: 10.1093/jac/dkm207.

Twigg RS., 1945. Oxidation-reduction aspects of resazurin. Nature. 155: 401–402. https://doi.org/10.1038/155401a0.

Vissa VD., Sakamuri RM., Li W., and Brennan PJ., 2009. Defining mycobacteria: shared and specific genome features for different lifestyles. Indian J Microbiol. 49: 11– 47. DOI: 10.1007/s12088-009-0006-0.

Webster DG., Le TD., More J., Manning T., Kunimoto D., LeBlanca D., Jhonson JA., Gray CA., 2010. Antimycobacterial screening of traditional medicinal plants using the microplate resazurin assay. Can J Microbiol. 56: 487-494. DOI: 10.1139/w10-035.

WHO., 2016. Library Cataloguing-in-Publication Data Global tuberculosis report 2016. World Health Organization. WHO/HTM/TB/.

Wu J., Ma G., Li H., Wu C., Tan Y., Zhang T., Chen F., Guo P., and Zhang X., 2014. Chemical constituents with antihyperlipidemic activities from Desmodium triquetrum. Chinese Herbal Medicines. 6: 324-327. https://doi.org/10.1016/S1674-6384(14)60049-6.




DOI: http://dx.doi.org/10.14499/indonesianjpharm30iss3pp199

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Indonesian Journal of Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

web
analytics View My Stats